Skip to NavigationSkip to content

Pharmafile - Research and Development News

Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular...
Johnson & Johnson have announced it has committed to ensuring more than $500 million is dedicated to R&D delivery programs over the next four...
Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the treatment of...
Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and...
Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinuamb) for patients with non-...
Bristol-Myers Squibb took the opportunity at ESMO 2019 to present new Phase 3 data on its blockbuster immunotherapy Opdivo in the treatment of...
Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating...
Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth around $243...
At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for the...
Johnson & Johnson have agreed to settle opioid litigation with two Ohio counties for roughly $20.4 million in a deal that includes combined $10...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches